Research

Longitudinal Cardiovascular Risk Study of Patients with Rheumatoid Arthritis.

For more information contact 310-206-4007.

Christina Charles-Schoeman, MD, MS

CANNABIDIOL: Therapeutic Response of Cannabidiol in Rheumatoid Arthritis.

For more information, contact 310-825-9956.

Veena K. Ranganath, MD, MS, RhMSUS

CANNABIS: Cannabis Anonymous Questionnaire in UCLA Rheumatology Patients.

For more information, contact 310-825-9956.

Veena K. Ranganath, MD, MS, RhMSUS

ACTHAR: Use of ACTHAR in Rheumatoid Arthritis Related Flares.

For more information, contact 310-825-9956.

Veena K. Ranganath, MD, MS, RhMSUS

RA-PROPR

For more information, contact 310-825-9956.

Veena K. Ranganath, MD, MS, RhMSUS

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus: Evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy.

For more information contact 310-825-2598.

Pro-inflammatory HDL Cholesterol: Evaluating biomarkers of risk for atherosclerosis in lupus. Involves a one-time blood draw.

For more information contact 310-794-9236.

Maureen McMahon, MD, MS

IDEAL: Evaluating the value of educational information about the risks and benefits of lupus medications. Implementation of the Decision-Aid for Lupus in practice settings for shared decision-making.

For more information contact 310-825-2598.

Maureen McMahon, MD, MS

Benlysta in Early Lupus: A study to evaluate the effects of Belimumab in patients recently diagnosed with lupus.

For more information contact 310-794-9236.

Maureen McMahon, MD, MS

AMG570: A study evaluating the safety and efficacy of AMG 570 in lupus patients.

For more information contact 310-825-2598.

Maureen McMahon, MD, MS

AMG592: Efficacy and safety of Efavaleukin Alfa in lupus patients.

For more information contact 310-825-2598.

Covid Booster Study: A study evaluating the benefit of additional COVID‐19 vaccine doses in patients with autoimmune diseases who are on immunosuppressive medications and may not have had a good response to initial or booster COVID-19 vaccination. For patients with a diagnosis of Systemic lupus Erythematosus (SLE), Rheumatoid arthritis (RA), Multiple sclerosis (MS), Systemic sclerosis (SSc) or Pemphigus.

For more information contact 310-825-2598.

Novartis: A study for safety, efficacy and tolerability of Secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis.

For more information contact 310-794-9236.

ALE10: A Phase 2, Double-Blind, Placebo-Controlled Trial of Mycophenolate Mofetil alone or with Voclosporin for Systemic Lupus: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment.

For more information contact 310-825-2598.

ITN Vibrant: A Phase 2a, Randomized, Placebo-Controlled, Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis.

For more information contact 310-794-9236.

PRiSE: Probing Remission in SLE: Blood and Brain.

For more information contact 310-794-9236.

PREVAIL-2: A Phase 2a, Randomized, Double-Blind, Placebo-controlled Trial of PRV-3279 Evaluation in Lupus.

For more information contact 310-825-2598.

Treatment

BRAVOS ITN075AI: Study of an Investigational Drug, Brentuximab Vedotin, for Diffuse Cutaneous Systemic Sclerosis.

For more information contact 310-825-9682.

Suzanne Kafaja, MD

MT-7117: Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis.

For more information contact 310-825-9682.

Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

For more information contact 310-825-9682.

Suzanne Kafaja, MD

Acceleron A1334-02: A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants with Systemic Sclerosis.

For more information contact 310-825-9682.

Emerald Health EHP-101: A Study to Assess the Safety, Tolerability, and Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis.

For more information contact 310-825-9682.

Scleroderma Lung Study III: Mycophenolate vs. Mycophenolate + Pirfenidone for systemic sclerosis-interstitial lung disease: This study compares two treatment regimens for systemic sclerosis-related lung disease: mycophenolate alone versus mycophenolate plus pirfenidone, an anti-fibrotic medication. This study is ongoing but currently closed to enrollment.

For more information, contact 310-794-6213.

PRA023: Safety and Efficacy Study of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD).

For more information, contact 310-794-6213.

Kadmon KD025-209: A placebo-controlled study to evaluate the efficacy and safety of KD025 (ROCK2 inhibitor) in subjects with diffuse cutaneous systemic sclerosis. This is a new investigational therapy for patients with systemic sclerosis. Patients can continue to take their regular medications while they participate in this study.

For more information, contact 310-794-6213.

Kadmon KD025-215: A study to evaluate the efficacy and safety of Belumosudil in subjects with diffuse cutaneous systemic sclerosis. This is a new investigational therapy for patients with systemic sclerosis. In this open-label study, all patients will have the opportunity to receive the investigational therapy. Patients can continue to take their regular medications while they participate in this study.

For more information, contact 310-794-6213.

Horizon: A study to evaluate the efficacy, safety, tolerability and pharmacokinetics of HZN-825 in patients with diffuse cutaneous systemic sclerosis. This is a new investigational therapy for patients with systemic sclerosis. Patients can continue to take their regular medications while they participate in this study.

For more information, contact 310-794-6213.

GRASP: Genome Research in African American Scleroderma Patients (GRASP).

For more information contact 310-825-9682.

Suzanne Kafaja, MD

SPIN: The Scleroderma Patient-Centered Intervention Network (SPIN) cohort collecting data on a regular basis related to problems likely to be important for many people living with scleroderma.

For more information contact 310-825-9682.

Suzanne Kafaja, MD

Skin Immune Response and Inflammation: Database and tissue bank aimed at evaluating differences in immune response in health and autoimmunity.

For more information contact 310-825-9682.

Validation of Musculoskeletal Ultrasound in Sclerosis Patients

For more information contact 310-825-9682.

Systemic Sclerosis Microbiome study: This study examines whether the gut microbiome contributes to the pathogenesis (cause) of systemic sclerosis. All patients with systemic sclerosis are eligible to participate in this study.

For more information, contact 310-794-6213.

Elizabeth Volkmann, MD, MS

The Gut Microbiome as a Screening Tool for ILD in Systemic Sclerosis: This study determines whether systemic sclerosis patients with interstitial lung disease (pulmonary fibrosis) have unique features of their gut microbiome. This study also seeks to determine whether the gut microbiome can be used to screen for the presence of interstitial lung disease in early systemic sclerosis.

For more information, contact 310-794-6213.

Biomarkers to Predict Treatment Response in Systemic Sclerosis-Interstitial Lung Disease: This is an NIH-sponsored study to discover novel biomarkers that predict response to therapy and outcomes in patients with systemic sclerosis-related interstitial lung disease. The outcomes of this research will allow us to develop personalized treatment plans for patients. All patients with systemic sclerosis-related interstitial lung disease are eligible to participate.

For more information, contact 310-794-6213.

Elizabeth Volkmann, MD, MS

CURESSC - Consortium of Universities to REsearch Scleroderma in Southern California: This study seeks to understand the genetics of systemic sclerosis and how changes in the blood vessels and fibroblasts (cells involved in fibrosis) contribute to skin disease in systemic sclerosis. The results of this study may reveal new treatment targets. Any patient with diffuse systemic sclerosis is eligible to participate.

For more information, contact 310-794-6213.

Elizabeth Volkmann, MD, MS

PET study of 68Ga-FAPi-46 in patients with interstitial lung disease: An exploratory biodistribution study with histopathology validation: This study aims to explore a novel radiographic assessment measure of fibroblast activation in patients with interstitial lung disease. The results may help us better understand the cause of interstitial lung disease and help us in making informed treatment decisions for patients. All patients with interstitial lung disease are eligible to participate.

For more information, contact 310-794-6213.

Elizabeth Volkmann, MD, MS

Scleroderma Clinical Trial Consortium: This study examines the gut microbiome of patients with systemic sclerosis from across the world to determine the impact of diet and environment on microbial composition in systemic sclerosis. This study will also evaluate whether the microbiome can serve as a marker of disease activity in systemic sclerosis.

For more information, contact 310-794-6213.

Elizabeth Volkmann, MD, MS

Treatment

Novartis CAIN457F2354: A study to assess the time course of response to secukinumab on joint inflammation using Power Doppler ultrasonography in patients with active psoriatic arthritis.

For more information contact 310-825-9682.

Suzanne Kafaja, MD

Observational

Longitudinal Cohort Study of Patients with Idiopathic Inflammatory Myopathies

For more information contact 310-206-4007.

Christina Charles-Schoeman, MD, MS

CSL Behring: A study to evaluate the efficacy safety, and pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) in adults with dermatomyositis (DM).

For more information contact 310-206-4007.

HDL: Evaluation of HDL function in patients with and without rheumatic disease.

For more information contact 310-206-4007.

No clinical trials open at this time.

Observational

CTD-ILD Registry: Any patient with a CTD-ILD

For more information contact 310-794-2466.

Elizabeth Volkmann, MD, MS

Treatment

Eicos ES-301: A study evaluating the safety and efficacy of IV Iloprost in subjects with systemic sclerosis experiencing symptomatic digital ischemic episodes.

For more information contact 310-825-9682.

Suzanne Kafaja, MD

IgPro10_2001: Study to evaluate the efficacy and safety of IgPro10 (intravenous immunoglobulin, Privigen®) for the treatment of adults with Systemic Sclerosis.

For more information contact 310-825-9682.

Alexion ALXN1210-DM-310: A multicenter study to evaluate the efficacy and safety of Ravulizumab in adult participants with dermatomyositis (DM).

For more information contact 310-206-4007.